Biohit Oyj’s Chinese joint venture Biohit HealthCare (Hefei) Co. Ltd production facility has passed official test requirements and has been granted a license enabling production and sales of products.
CEO Semi Korpela, Biohit Oyj: ‘The approval and official permit process have taken longer than anticipated, but are finally completed. Our joint venture can now produce GastroPanel®-products for the promising Chinese markets cost effectively and in large scale. The GastroPanel® (1,2), which is highly informative and unique in China and elsewhere in the world doesn’t have the serious medical deficiencies as do the helicobacter tests (e.g. 13C urea breath test) still in use (3).’
CEO Liu Feng, Biohit HealthCare (Hefei) Co. Ltd: ‘We have finalised the production facility utilising state of the art technology and process automation for the production, warehousing and logistics of GastroPanel®-products for the Chinese domestic market. The production capacity has been tailored to correspond with the capacity needs of a possible population based screening program.’
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com